X
FDA to review Sanofi’s Dupixent in asthma
https://pharmaphorum.com/news/fda-review-sanofis-dupixent-asthma/
respiratory
Rumours of $1.65bn GSK bid for respiratory partners Vectura
GlaxoSmithKline could be poised to acquire its respiratory partner, UK biotech Vectura, for $1.65bn.
Inhalation technology: the future of effective respiratory treatments
Simon Moore discusses non-clinical development channels: technical strategies, formulations and devices.
AZ’s asthma drug Fasenra approved in EU
A further 3,400 children are eligible for treatment with Orkambi
Sunovion’s COPD nebuliser approved in US
Device aims to help patients get a full dose of medication